Cornelis P. Vlaar

University of Puerto Rico, Medical Sciences Campus

Also affiliated with University of Puerto Rico System, Clinical Research Puerto Rico

Biochemistry, Genetics and Molecular BiologyMedicineMaterials Science

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans”.

Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans

Drug Metabolism and Personalized Therapy(2020)10.1515/dmdi-2020-0135

N/A

0DataRank · unranked

1 citations

Camila de las Barreras, Gledys Reynaldo, Leyanis Rodríguez‐Vera, Cornelis P. Vlaar, Vilmali Lopez Mejias +5 more

Efficacy of Rac and Cdc42 Inhibitor MBQ-167 in Triple-negative Breast Cancer

Molecular Cancer Therapeutics(2021)10.1158/1535-7163.mct-21-0348

N/A

0DataRank · unranked

24 citations

Jean F. Ruiz-Calderon, Hector Picon, Luis D. Borrero-Garcia, Irmaris Lopez, Linette Castillo-Pichardo +8 more

The Rac inhibitor HV-107 as a potential therapeutic for metastatic breast cancer

Molecular Medicine(2023)10.1186/s10020-023-00678-7

N/A

0DataRank · unranked

2 citations

Jescelica Ortiz, Eliud Hernandez O'Farril, Cornelis P. Vlaar, Mikhail Inyushin, Yuriy Kucheryavykh +2 more

New insights into the role of VKORC1 polymorphisms for optimal warfarin dose selection in Caribbean Hispanic patients through an external validation of a population PK/PD model

Biomedicine & Pharmacotherapy(2023)10.1016/j.biopha.2023.115977

N/A

0DataRank · unranked

2 citations

Gledys Reynaldo Fernández, Stephanie Reyes-González, Camila de las Barreras, Leyanis Rodríguez‐Vera, Cornelis P. Vlaar +5 more

Data from Efficacy of Rac and Cdc42 Inhibitor MBQ-167 in Triple-negative Breast Cancer

(2023)10.1158/1535-7163.c.6543291

N/A

0DataRank · unranked

0 citations

Jean F. Ruiz-Calderón, Hector Picon, Luis D. Borrero-García, Irmaris Lopez, Linette Castillo‐Pichardo +8 more

Data from Efficacy of Rac and Cdc42 Inhibitor MBQ-167 in Triple-negative Breast Cancer

(2023)10.1158/1535-7163.c.6543291.v1

N/A

0DataRank · unranked

0 citations

Jean F. Ruiz-Calderón, Hector Picon, Luis D. Borrero-García, Irmaris Lopez, Linette Castillo‐Pichardo +8 more

A review of precision medicine in developing pharmaceutical products: Perspectives and opportunities

International Journal of Pharmaceutics(2024)10.1016/j.ijpharm.2024.125070

N/A

0DataRank · unranked

8 citations

Indumathi Sathisaran, Francheska Reyes Figueroa, Stephanie R. Reyes, Marisol López-Nieves, Cornelis P. Vlaar +6 more

Efficacy and delivery strategies of the dual Rac/Cdc42 inhibitor MBQ-167 in HER2 overexpressing breast cancer

Translational Oncology(2024)10.1016/j.tranon.2024.101928

N/A

0DataRank · unranked

5 citations

Michael J. Rivera-Robles, Annelis O. Sánchez-Álvarez, Pablo E. Vivas‐Mejía, Miciely Aponte-Reyes, Ailed Cruz‐Collazo +6 more